Emerging drugs which target the renin–angiotensin–aldosterone system

Bibliography

• Steckelings UM, Unger T. The renin-angiotensin-aldosterone system. Manual of Hypertension of the European Society of Hypertension. Informa Healthcare; London: 2008. p. 110-16
   Google Scholar
• Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010;50:439-65
   PubMed Web of Science ®Google Scholar
• Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;16:747-803
   Google Scholar
• Nguyen G, Delarue F, Burckle C, Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27
   PubMed Web of Science ®Google Scholar
• Burckle C, Bader M. Prorenin and its ancient receptor. Hypertension 2006;48:549-51
   PubMed Web of Science ®Google Scholar
• Sihn G, Rousselle A, Vil'ianovich L, Physiology of the (pro)renin receptor: wnt of change? Kidney Int 2010;78:246-56
   PubMed Web of Science ®Google Scholar
• Alenina N, Xu P, Rentzsch B, Bader M. Genetically altered animal models for mas and angiotensin-(1-7). Exp Physiol 2008;93:5328-537
   Google Scholar
• Steckelings UM, Rompe F, Kaschina E, The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst 2010;11:67-73
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Kaschina E, Unger T. The AT2 receptor – a matter of love and hate. Peptides 2005;26:1401-9
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Bramlage P, Bohm M, Volpe M, A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) 2010;12:666-77
   PubMed Web of Science ®Google Scholar
• Kotchen TA. Hypertension control: trends, approaches, and goals. Hypertension 2007;49:19-20
   PubMed Web of Science ®Google Scholar
• Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000;5:167-73
   PubMedGoogle Scholar
• Redon J. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? Curr Opin Nephrol Hypertens 2005;14:448-52
   PubMed Web of Science ®Google Scholar
• Atkins RC. The epidemiology of chronic kidney disease.. Kidney Int Suppl 2005;94:S14-18
   PubMedGoogle Scholar
• Agodoa LY, Jones CA, Held PJ. End-stage renal disease in the USA: data from the United States Renal Data System. Am J Nephrol 1996;16:7-16
   PubMed Web of Science ®Google Scholar
• Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006;60:1471-83
   PubMed Web of Science ®Google Scholar
• Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone 2003;5:12-21
   PubMedGoogle Scholar
• Buch H, Vinding T, Nielsen NV. Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001;108:2347-57
   PubMed Web of Science ®Google Scholar
• Banerjee D, Materson BJ. Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease. Curr Hypertens Rep 2002;4:445-52
   PubMed Web of Science ®Google Scholar
• Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002;89:11A-6A
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension-European Society of Cardiology guidelines committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 1965;24:163-9
   PubMed Web of Science ®Google Scholar
• Stamler JF, Brody MJ, Phillips MI. The central and peripheral effects of captopril (SQ 14225) on the arterial pressure of the spontaneously hypertensive rat. Brain Res 1980;186:449-503
   Google Scholar
• Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010;123:1016-30
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005;53:373-88
   PubMed Web of Science ®Google Scholar
• Sleight P, Yusuf S, Pogue J, Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130-1
   PubMed Web of Science ®Google Scholar
• Angiotensin-receptor blocker approved as antihypertensive. Am J Health Syst Pharm 1995;52:1368
   PubMedGoogle Scholar
• Wong PC, Barnes TB, Chiu AT, Losartan (DuP 753), an orally active nonpeptide angiotensin II receptor antagonist. Cardiovasc Drug Rev 1991;9:317-39
   Google Scholar
• Yusuf S, Teo K, Anderson C, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83
   PubMed Web of Science ®Google Scholar
• Vidt DG. Telmisartan, ramipril, or both in patients at high risk for vascular events. Curr Hypertens Rep 2008;10:343-4
   PubMed Web of Science ®Google Scholar
• McMurray JJ. Angiotensin inhibition in heart failure. J Renin Angiotensin Aldosterone Syst 2004;5(Suppl 1):S17-22
   PubMed Web of Science ®Google Scholar
• Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol 2004;15(Suppl 1):S64-70
   PubMed Web of Science ®Google Scholar
• Sjolie AK, Dodson P, Hobbs FR. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract 2011;65:148-53
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B, Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010;105:21A-9A
   PubMedGoogle Scholar
• Bader M, Ganten D. Regulation of renin. J Mol Med 2000;78:130-9
   PubMed Web of Science ®Google Scholar
• Kurtz A. Renin release: sites, mechanisms, and control. Annu Rev Physiol 2011;73:377-99
   PubMed Web of Science ®Google Scholar
• Habashi JP, Doyle JJ, Holm TM, Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332:361-5
   PubMed Web of Science ®Google Scholar
• Li J, Culman J, Hortnagl H, Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005;19:617-19
   PubMed Web of Science ®Google Scholar
• Naito T, Ma LJ, Yang H, Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 2010;298:F683-91
   PubMed Web of Science ®Google Scholar
• Duke LM, Evans RG, Widdop RE. AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats. Am J Physiol Heart Circ Physiol 2005;288:H2289-97
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R, Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7
   PubMed Web of Science ®Google Scholar
• Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957;106:439-53
   PubMed Web of Science ®Google Scholar
• Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410
   PubMed Web of Science ®Google Scholar
• Lee HY, Oh BH. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Rev Cardiovasc Ther 2009;7:251-7
   PubMedGoogle Scholar
• Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002;970:89-100
   PubMed Web of Science ®Google Scholar
• Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis 2010;52:393-400
   PubMed Web of Science ®Google Scholar
• Fitzgerald N, Fitzgerald JD. Aldosterone antagonists: a model of translational medicine. Dialogues Cardiovasc Med 2009;14:118-25
   Google Scholar
• Jeunemaitre X, Chatellier G, Kreft-Jais C, Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-5
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Lee AF, Morton JJ, How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Pitt B, White H, Nicolau J, Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-31
   PubMed Web of Science ®Google Scholar
• Williams GH, Burgess E, Kolloch RE, Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004;93:990-6
   PubMed Web of Science ®Google Scholar
• Weinberger MH, White WB, Ruilope LM, Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005;150:426-33
   PubMed Web of Science ®Google Scholar
• White WB, Duprez D, St HR, Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6
   PubMed Web of Science ®Google Scholar
• Krum H, Nolly H, Workman D, Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23
   PubMed Web of Science ®Google Scholar
• Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-8
   PubMed Web of Science ®Google Scholar
• Muldowney JA III, Schoenhard JA, Benge CD. The clinical pharmacology of eplerenone. Expert Opin Drug Metab Toxicol 2009;5:425-32
   PubMed Web of Science ®Google Scholar
• Yamaji M, Tsutamoto T, Kawahara C, Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am Heart J 2010;160:915-21
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16
   PubMed Web of Science ®Google Scholar
• Violin JD, DeWire SM, Yamashita D, Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010;335:572-9
   PubMed Web of Science ®Google Scholar
• Rakesh K, Yoo B, Kim IM, beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 2010;3:ra46
   Google Scholar
• Duchene J, Bader M. Bradykinin B2 receptor agonism: A novel therapeutic strategy for myocardial infarction? Am J Hypertens 2010;23:459
   PubMed Web of Science ®Google Scholar
• Kuwahara K, Nakao K. Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones. Endocr J 2010;57:555-65
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003;41:383-9
   PubMed Web of Science ®Google Scholar
• Gros C, Noel N, Souque A, Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-14
   PubMed Web of Science ®Google Scholar
• Jullien N, Makritis A, Georgiadis D, Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem 2010;53:208-20
   PubMed Web of Science ®Google Scholar
• Thorin E, Clozel M. The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol 2010;60:1-26
   PubMedGoogle Scholar
• Akif M, Schwager SL, Anthony CS, Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide. Biochem J 2011;436:53-9
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401-14
   PubMed Web of Science ®Google Scholar
• Lucchese B. Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial. Nat Rev Nephrol 2010;6:383
   PubMedGoogle Scholar
• Iwata N, Tsubuki S, Takaki Y, Metabolic regulation of brain Abeta by neprilysin. Science 2001;292:1550-2
   PubMed Web of Science ®Google Scholar
• Becker M, Siems WE, Kluge R, New function for an old enzyme: NEP deficient mice develop late-onset obesity. PLoS One 2010;5(9):e12793. doi:10.1371/journal.pone.0012793
   PubMedGoogle Scholar
• Martelli A, Breschi MC, Calderone V. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des 2009;15:614-36
   PubMed Web of Science ®Google Scholar
• Nguyen G. Renin, (pro)renin and receptor: an update. Clin Sci (Lond) 2011;120:169-78
   PubMed Web of Science ®Google Scholar
• Schefe JH, Menk M, Reinemund J, A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006;99:1355-66
   PubMed Web of Science ®Google Scholar
• Inagami T, Nakagawa T, Ichihara A, Renin/prorenin receptor, (P)RR, in end-organ damage: current issues in 2007. J Am Soc Hypertens 2008;2:205-9
   PubMed Web of Science ®Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y, Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004;114:1128-35
   PubMed Web of Science ®Google Scholar
• Funke-Kaiser H, Zollmann FS, Schefe JH, Unger T. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res 2010;33:98-104
   PubMed Web of Science ®Google Scholar
• Nariai T, Fujita K, Mori M, SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na(+) excretion activity. J Pharmacol Sci 2011;115:346-53
   PubMed Web of Science ®Google Scholar
• Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010;7:431-41
   PubMed Web of Science ®Google Scholar
• Fiebeler A, Nussberger J, Shagdarsuren E, Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005;111:3087-94
   PubMed Web of Science ®Google Scholar
• Lea WB, Kwak ES, Luther JM, Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009;75:936-44
   PubMed Web of Science ®Google Scholar
• Mulder P, Mellin V, Favre J, Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008;29:2171-9
   PubMed Web of Science ®Google Scholar
• Amar L, Azizi M, Menard J, Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010;56:831-8
   PubMed Web of Science ®Google Scholar
• Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005;10:15-22
   PubMed Web of Science ®Google Scholar
• Brown MJ. Success and failure of vaccines against renin-angiotensin system components. Nat Rev Cardiol 2009;6:639-47
   PubMed Web of Science ®Google Scholar
• Tissot AC, Maurer P, Nussberger J, Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008;371:821-7
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875-9
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-16
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Shenoy V, Qi Y, Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011;96:287-94
   PubMed Web of Science ®Google Scholar
• Lula I, Denadai AL, Resende JM, Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 2007;28:2199-210
   PubMed Web of Science ®Google Scholar
• Fraga-Silva RA, Costa-Fraga FP, Sousa FB, An orally-active formulation of angiotensin-(1-7) produces antithrombotic effect. Clinics 2011; In press
   PubMed Web of Science ®Google Scholar
• Savergnini SQ, Beiman M, Lautner RQ, Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the Mas receptor. Hypertension 2010;56:112-20
   PubMed Web of Science ®Google Scholar
• Marques FD, Ferreira AJ, Sinisterra RD, An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011;57:477-83
   PubMed Web of Science ®Google Scholar
• Wiemer G, Dobrucki LW, Louka FR, AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 2002;40:847-52
   PubMed Web of Science ®Google Scholar
• Wan Y, Wallinder C, Plouffe B, Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004;47:5995-6008
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Larhed M, Hallberg A, Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 2011;11:187-92
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9
   PubMed Web of Science ®Google Scholar
• Radonic T, De Witte P, Baars MJ, COMPARE study group: Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials 2010;12:11-3104
   Google Scholar
• Habashi JP, Doyle JJ, Holm TM, Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332:361-5
   PubMed Web of Science ®Google Scholar